TD Cowen Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $254
BeiGene Canada Proud National Sponsor of the Leukemia & Lymphoma Society of Canada's 2024 Light The Night
TD Cowen Keeps Their Buy Rating on BeiGene (BGNE)
Express News | The Committee For Medicinal Products For Human Use Of The European Medicines Agency Issued Positive Opinions Recommending An Extended Authorization For BeiGene's Tevimbra (Tislelizumab) In Gastric Or Gastroesophageal Junction Adenocarcinoma And...
BeiGene Receives Positive CHMP Opinions for TEVIMBRA as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma
Express News | Beigene Receives Positive Chmp Opinions for Tevimbra® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma
Nomura Adjusts BeiGene's Price Target to HK$174.91 From HK$158.37, Keeps at Buy
Zhaojin International: China Meheco Group's industry is expected to "outperform the market" Focus on the health insurance opportunities of innovative varieties.
CICC released research reports stating that benefited from overseas interest rate cuts and domestic macroeconomic improvement, the pharmaceutical industry, as a high elasticity sector, is expected to outperform the broader market. The firm is bullish on CXO, innovative drugs, consumer healthcare, and medical equipment sectors; bullish on Wuxi Apptec (02359), BeiGene (06160), Innovent Bio (01801), Kendallo Bio (06990), Juji Biotech (02367), 3SBio (01530), Shenzhen Mindray Bio-medical Electronics (300760.SZ). The report stated that the MSCI China Healthcare Index has cumulatively declined by 14.1% year-to-date, underperforming the MSCI China Index.
Trending Industry Today: ZAI LAB Leads Gains In Biotechnology Stocks
Recent 7.2% Pullback Isn't Enough to Hurt Long-term BeiGene (NASDAQ:BGNE) Shareholders, They're Still up 60% Over 5 Years
BeiGene Highlights Waldenström's Macroglobulinemia Innovation at IWWM 2024
gtja: Bullish on innovative drugs policy, expected to continue to advance. Chinese patent medicine centralized procurement may face accelerated expansion.
With the support of the entire chain, innovative drugs have seen a series of bullish policies introduced in various regions, and favorable policies are expected to continue to advance in the future; centralized procurement of chinese patent medicine may accelerate its expansion.
Trending Industry Today: WUXI APPTEC Leads Losses In Biotechnology Stocks
Top Gap Ups and Downs on Monday: BLCO, SIRI, ICL, HMY and More
Shares of US-listed Chinese Stocks Are Trading Lower on Continued Weakness Amid Stimulus Uncertainty.
Hong Kong Stocks Fall on Uncertainty in Further Stimulus; Pharma Firms Lead Decline
Goldman Sachs Raises China Economic Growth Forecasts
Beigene Insider Sold Shares Worth $3,756,092, According to a Recent SEC Filing
China's Central Bank Launches Swap Facility to Boost Stock Market
Hong Kong stock market anomaly | Beigene (06160) is currently up more than 8%, officially listed in the USA for tislelizumab, the company's operation losses continue to narrow.
Beigene (06160) is now up more than 8%, as of the time of publication, up 7.32%, trading at 149.6 Hong Kong dollars, with a turnover of 0.393 billion Hong Kong dollars.